Clinical Research at Crossroads: The Trends Reshaping the Industry
A 2026-2027 Outlook -A Sikara Consultancy Research Briefing
Executive summary
Clinical research in 2026 sits at the intersection of three forces: artificial intelligence maturing from pilot to production, regulatory modernization finally taking effect after years of drafting, and mounting financial pressure on the sites that execute trials. In addition to these three, decentralization of clinical trials and personalized medicine is taking traction.
The global clinical trials market is on track to expand from $127.16 billion in 2025 to $135.51 billion in 2026, and to reach $176.32 billion by 2030; growth increasingly driven by AI adoption and decentralized trial models rather than simple volume increase. At the same time, more than 70% of research sites report active financial stress, and federal funding volatility has already disrupted hundreds of active studies.
The sponsors and sites that adapt fastest to this combination of technological opportunity and operational strain will define the next five years of the industry.
1. AI-led transformation of clinical research
AI adoption in clinical research has moved from experimentation to measurable market scale. The broader AI-based clinical trials market grew from $7.73 billion in 2024 to $9.17 billion in 2025, with a projected compound annual growth rate of nearly 19% reaching $21.79 billion by 2030. Separately, AI-driven drug discovery reached an estimated $2.6 billion market by early 2026, with more than 173 AI-originated drug programs in clinical development and 15 to 20 expected to enter pivotal trials in 2026 alone.
Where AI is having real impact right now:
•Predictive analytics and drug discovery. AI is shortening discovery-to-candidate timelines, though 2026 is best described as an inflection point where Phase III results will determine whether AI-designed drugs can deliver at scale.
•Personalized Treatment Plans: AI will be instrumental in developing personalized treatment regimens based on a patient’s genetic makeup, lifestyle, and other variables. This allows clinicians to provide more effective and tailored care, shifting away from the "one-size-fits-all" approach.
•Automation of Data Analysis: AI will automate many aspects of data collection and analysis, including the detection of anomalies in trial data and the optimization of trial protocols. This will improve the accuracy and speed of clinical trials.
•Automation and virtual assistants remain active but incremental use cases, rather than the primary driver of AI market growth, which is concentrated in discovery and predictive modeling. AI-driven virtual assistants will play an increasing role in patient communication, answering queries, reminding patients to take medications, and helping them understand clinical trial protocols. These tools will make trials more patient-friendly and efficient.
•Regulatory clarity is catching up. FDA published draft guidance in 2025 on AI use in regulatory decision-making. Final guidance has been released recently.
2. Patient-centered research and personalized medicine
The shift toward patient-centered design is real but is being driven as much by regulatory modernization as by sponsor preference. Real-world data and real-world evidence are increasingly built into trial design rather than treated as a post-approval add-on, and adaptive, patient-centric protocols are gaining broader regulatory acceptance as ICH E6(R3) takes effect. Digital tools such as apps, wearables, ePRO remain central to this shift, though their value depends on deployment discipline: tools that duplicate rather than replace existing site workflows add burden rather than remove it.
Key drivers are detailed below:
•Patient Engagement and Recruitment: In clinical trials, patient engagement will become a top priority. Digital tools (e.g., apps and wearables) will help track patient symptoms, behavior, and treatment outcomes in real-time, allowing researchers to gather more accurate, patient-relevant data. Social media platforms, patient advocacy groups, and online communities will also play a more significant role in recruitment, helping sites find participants who are truly interested in the study and understand the potential benefits.
•Precision Medicine: Personalized medicine, where treatments are tailored to individual genetic profiles, will be more prevalent. This trend will expand with new genetic sequencing technologies, allowing trials to be more focused on genetic subsets of diseases. AI will also support clinicians in choosing the right personalized treatment options based on massive datasets from a variety of sources.
•Real-World Data (RWD) and Real-World Evidence (RWE): The use of RWD and RWE will grow significantly, allowing researchers to gather data outside of controlled clinical settings. By using electronic health records (EHRs), wearables, and other forms of data collection, clinical trials will become more adaptable and reflect broader populations. This approach will also help identify new patient subgroups and predict treatment outcomes.
•Patient-Centric Trial Design: Trials will be designed with the patient in mind, incorporating feedback from participants to ensure that protocols are as non-intrusive and convenient as possible. This might include flexible scheduling, remote monitoring, and personalized care plans. "Adaptive trial designs" will be a growing trend, where trial protocols can be adjusted based on interim results, helping to ensure that patients benefit from the trial as it progresses.
3. Decentralized trials (DCTs)
Market analysts broadly agree DCTs are growing at double-digit rates, though the exact size varies significantly by methodology. Estimates for 2026 range from roughly $10.3 billion to $11.3 billion, with 2030 projections between $16.7 billion and $19.6 billion depending on the analyst. Growth drivers are consistent across reports: AI and machine learning integration, blockchain-enabled data security, rising prevalence of rare and chronic diseases favoring decentralized models, increased use of real-world evidence, and expanding 5G connectivity. Oncology is a particular bright spot indicating that oncological disorders hold roughly 15% share of the virtual/decentralized trials market in 2026 and are projected to grow at nearly 12% CAGR, since intensive treatment side effects make travel to trial sites especially burdensome for cancer patients.
Decentralized clinical trials will likely become a dominant model soon, with several key components driving their growth:
•Remote Monitoring and Data Collection: Technologies like wearables, telemedicine, and mobile health apps will make it easier for patients to participate in trials from their homes or local clinics. Remote data collection will reduce the burden on participants, making it easier for them to stay involved in trials without having to travel to central sites.
•Decentralized Data Management: With trials conducted remotely, clinical sites will leverage cloud-based platforms and AI to manage data, ensuring real-time access to clinical data from multiple locations. This approach can improve data integrity and reduce delays in trial timelines.
•Improved Access for Participants: Decentralized trials will make it easier for patients in rural or underserved areas to participate in clinical research, leading to a more diverse and representative pool of trial participants.
•Challenges in Decentralized Trials: While decentralized trials offer many benefits, they also present challenges, such as regulatory compliance, data security, and the need for robust patient education. In 2027 and beyond, organizations will need to focus on overcoming these challenges with more sophisticated systems for remote monitoring, telemedicine integration, and regulatory guidelines that allow for flexibility in remote data collection and management.
4. Financial pressures facing clinical research sites
Over 70% of sites report experiencing financial stress, with many taking out loans to sustain operations while awaiting reimbursement. This is compounded by federal funding volatility: more than $83 million in federal research funding was canceled and many NIH-funded clinical trials lost support within a six-month window, exposing how exposed trial timelines are to political and budget decisions well outside any single protocol. Sponsors and sites need to work together to streamline process, engage patients and work within finance and resource constrained environments.
Clinical research sites will face ongoing financial uncertainty in 2026, due to fluctuating funding, increasing competition, and rising costs. To prepare for this, sites should focus on several strategies:
•Diversification of Revenue Streams: Sites can diversify their sources of income by seeking out partnerships with pharmaceutical companies, biotech firms, and contract research organizations (CROs). Additionally, some sites are branching into providing additional services such as patient recruitment, data analytics, or regulatory consultation.
•Operational Efficiency: To remain competitive, sites must leverage technology to streamline operations. Automating administrative tasks, optimizing clinical trial management software, and using AI for data management will help sites cut down on overhead costs. AI can also be used to optimize trial recruitment, ensuring that sites don't spend unnecessary time and resources on unqualified participants.
•Collaboration and Network Expansion: Sites can join larger networks or research consortia, which could provide access to more trials and resources. Collaborative partnerships with academic institutions, hospitals, and other research entities can help offset costs and ensure a steady flow of research opportunities.
•Adapting to Regulatory Changes: Sites will need to stay agile to adjust to evolving regulatory requirements, particularly with the rise of decentralized trials and data privacy concerns. This may require investing in compliance training and adopting new tools to manage remote trial compliance.
•Patient-Centric Payment Models: With the rise of patient-centered research, financial models will need to adapt. Sites should consider creating more flexible payment options for patients, as well as reimbursement models that focus on patient outcomes and engagement rather than volume-based models. Offering easier access to care (e.g., home-based testing or virtual appointments) could also help retain participants in long-term studies.
5. Regulatory landscape: 2026 status
- ICH E6(R3) / modernized GCP. Principles and Annex 1 were finalized January 6, 2025, officially superseding the 2016 ICH E6(R2). FDA released its final guidance adopting E6(R3) in September 2025, incorporating flexible, risk-based approaches to trial design, conduct, and technology. Annex 2 reached final adoption on June 3, 2026, and takes legal effect in the EU on January 15, 2027.
- FDA's animal testing phase-out. FDA published its roadmap on April 10, 2025, to reduce, refine, and replace animal testing with New Approach Methodologies (NAMs), initially focused on monoclonal antibodies. FDA confirmed in April 2026 that it had achieved its Year 1 implementation goals, ahead of where the original source framework placed this trend. FDA aims for animal studies to become the exception rather than the default within three to five years.
- AI regulatory guidance. Draft guidance on AI in regulatory submissions has been available since January 2025; final guidance is expected around Q2 2026 but had not been finalized as of this writing.
- Operation TrailBlazer Released. Reduces Clinical Trial turnaround times by 6-12 months
Regulatory Milestone Timeline
April 2025 FDA animal testing roadmap established
September 2025 FDA final guidance on ICH E6(R3) released
April 2026 FDA confirms Year 1 goals on animal testing roadmap
June 2026 ICH E6(R3) Annex 2 Finalized
July 2026 HHS releases Operation TrailBlazer for Clinical Trials
High- level 2026 Regulatory Themes
•Modernized GCP ICH E6(R3). Principles/Annex 1 final since Jan 2025; FDA guidance final Sept 2025; Annex 2 finalized June 2026. Risk-based monitoring and vendor oversight accountability
•FDA animal testing phase-out. Roadmap issued April 2025; Year 1 goals confirmed achieved April 2026. NAMs are being actively integrated into review pathways now
•AI regulatory guidance. Draft since Jan 2025; final expected ~Q3 2026, not yet confirmed.
•Diversity Action Plans. Not advancing - draft withdrawn Jan 2025; unfinalized as of May 2026. No near-term enforceable diversity-enrollment mandate should be assumed
•HHS released Operation TrailBlazer recently to modernize clinical trials. The pilot program, part of the broader Operation TrialBlazer initiative, aims to reduce early trial timelines by six to 12 months, with officials describing the plan as necessary to counter competitive pressure from China, whose share of early-phase clinical studies surpassed the U.S. in 2021, with China's total registered trial count also now exceeding the U.S.
Key points of Operation TrailBlazer:
-Expedited IND pilot program - a rolling submission platform to reduce clinical holds
-AI-powered dose selection guidance - replacing animal models with quantitative systems pharmacology for first-in-human trials
-Master protocol frameworks - enabling more adaptive, efficient trial designs
-One-pivotal-trial default - one rigorous study plus confirmatory evidence can now support approval
-Real-time clinical trials - FDA receiving live data signals as trials run, eliminating inter-phase gaps
-A dedicated IND Navigator webpage and call center - especially important for smaller sponsors without large regulatory teams
-NIH is also building reusable trial infrastructure networks, designed to be activated for multiple studies, not rebuilt from scratch each time.
Why this Matters
-Streamlined IND pathways lower the barrier to trial activation. AI-assisted dose modeling reduces preclinical burden.
-Real-time data sharing creates a faster feedback loop between sites and regulators.
-Shift of the regulatory headwinds that made Phase 1 research feel out of reach for community settings are making these trials more accessible.
Conclusion
The throughline across these five trends is not any single technology or regulation, it's a widening gap between what's operationally possible and what most research organizations are staffed, funded, and structured to execute. AI has moved from pilot to measurable market scale, but the organizations capturing that value are the ones with the data infrastructure and governance to use it, not simply the ones with access to it. ICH E6(R3) and the FDA's animal-testing roadmap are no longer future-tense commitments; they are active obligations as of 2026, and sites without documented risk-based monitoring or NAM-readiness are already behind rather than early. Decentralized trials continue to expand for defensible reasons but that growth still runs through sites that are more financially strained than at almost any point in the last decade.
That financial strain is the fact most likely to be underweighted by organizations reading this report. A market growing toward $176 billion by 2030 can coexist with more than 70% of the sites executing that growth reporting active financial distress i.e. scale at the market level does not translate automatically into stability at the site level. Sponsors and health systems that treat 2026's technological and regulatory shifts as purely a capability question, without addressing the operational and financial fragility underneath them, will find that the infrastructure to capitalize on AI, decentralization, and modernized GCP simply isn't there when it's needed.
The organizations best positioned for 2027 and beyond will be the ones that pair technical readiness with site-level investment: real data governance ahead of AI adoption, documented risk-based monitoring ahead of audit rather than in response to it, and revenue models for sites that don't assume indefinite absorption of reimbursement delays and funding volatility. The regulatory and technological pieces of this outlook are, for the most part, now settled and knowable. Whether the industry builds the operational foundation to act on them is the open question for the next eighteen months.
References
-
FDA, "E6(R3) Good Clinical Practice (GCP) — Final Guidance," September 2025. fda.gov
-
Federal Register, "E6(R3) Good Clinical Practice Guidance Availability Notice." federalregister.gov
-
ICH, "E6(R3) Annex 2 Final Guideline," adopted June 3, 2026. database.ich.org
-
EMA, "ICH E6 Good Clinical Practice Scientific Guideline." ema.europa.eu
-
FDA, "FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development," April 2026. fda.gov
-
FDA, "FDA Announces Plan to Phase Out Animal Testing Requirement," April 2025. fda.gov
-
FDA, "Artificial Intelligence for Drug Development." fda.gov
-
AJMC, "FDA Quietly Removes Draft Guidance on Diversity in Clinical Trials Following Executive Order on DEI." ajmc.com
-
MedDeviceGuide, "Medical Device Clinical Trial Diversity: FDA Diversity Action Plans status as of May 2026." meddeviceguide.com
-
GlobeNewswire, "Global Clinical Trials Market to Reach $176.32 Billion by 2030," July 2026. globenewswire.com
-
Research and Markets, "Decentralized Clinical Trials Market Report 2026." researchandmarkets.com
-
Wiley, "A Critical Review of the FDA's Draft Guidance on AI in Drug and Biological Product Regulation," 2026. onlinelibrary.wiley.com
-
IntuitionLabs, "AI Applications in the Drug Development Pipeline." intuitionlabs.ai
-
Applied Clinical Trials Online, "Sites Under Pressure: What Clinical Research Sites Need to Operate, Compete, and Deliver." appliedclinicaltrialsonline.com
-
Cromos Pharma, "Clinical Research in 2026: What's Changing and Why It Matters." cromospharma.com
-
Objective Investment Banking & Valuation, "Valuation of Clinical Research Sites," 2025. objectiveibv.com
-
HHS, "Operation TrialBlazer: HHS Roadmap to Maintaining U.S. Leadership in Early Clinical Research and Development," June 22, 2026. hhs.gov
-
Applied Clinical Trials Online, "HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research." appliedclinicaltrialsonline.com